The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations
Open accessAbstract
Exacerbations of chronic obstructive pulmonary disease (COPD) are associated with worse health and increased healthcare utilisation. The Inhaled Steroids in Obstructive Lung Disease in Europe (ISOLDE) study in COPD showed a 26% reduction in the yearly rate of exacerbations in patients treated with fluticasone propionate (FP) compared to placebo, but did not indicate which patients showed greatest benefit. In this study the patients were stratified into mild and moderate‐to‐severe COPD using the American Thoracic Society criterion of forced expiratory volume in one second (FEV 1) 50% predicted, and the total number of exacerbations and those requiring treatment with oral corticosteroids were examined. There were 391 (195 FP) patients with mild COPD and 359 (180 FP) patients with moderate‐to‐severe disease. The exacerbation rate was highly skewed in mild disease, but more normally distributed in moderate‐to‐severe disease. FP reduced the overall exacerbation rate in moderate‐to‐severe disease (FP median rate 1.47 yr−1, placebo 1.75 yr−1), but not in mild disease (FP 0.67 yr−1, placebo 0.92 yr−1). FP use was associated with fewer patients with ≥1 exacerbation·yr−1 being treated with oral corticosteroids (mild: FP 8%, placebo 16%; moderate‐to‐severe: FP 17%, placebo 30%). Effects of fluticasone propionate on exacerbations were seen predominantly in patients with a postbronchodilator forced expiratory volume in one second <50% predicted. These data support recommendations in the Global Initiative for Chronic Obstructive Disease treatment guidelines that inhaled corticosteroids should be considered in patients with moderate‐to‐severe chronic obstructive pulmonary disease who experience recurrent exacerbations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Self-citation
Cited by
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Self-citationRabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. A., Calverley, P., Fukuchi, Y., Jenkins, C., Rodriguez-Roisin, R., van Weel, C., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-456so · Cited by 4,925
Self-citationCOPD exacerbations: Defining their cause and prevention
Wedzicha, J. A., & Seemungal, T. A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61382-8 · Cited by 1,370
Outcomes for COPD pharmacological trials: from lung function to biomarkers
Cazzola, M., MacNee, W., Martinez, F. J., Rabe, K. F., Franciosi, L. G., Barnes, P. J., Brusasco, V., Burge, P. S., Calverley, P. M. A., Celli, B. R., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00099306 · Cited by 858
Self-citationO’Donnell, D. E., Aaron, S., Bourbeau, J., Hernandez, P., Marciniuk, D. D., Balter, M., Ford, G., Gervais, A., Goldstein, R., Hodder, R., et al. (2007) · Canadian Respiratory Journal · doi:10.1155/2007/830570 · Cited by 693
Metadata
- Authors
- Jones, P. W., Willits, L. R., Burge, P. S., & Calverley, P. M. A.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2003-01
- Volume
- 21
- Issue
- 1
- Pages
- 68-73
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2133343848
- Cited by
- 249
- References
- 1
- FWCI
- 22.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. https://app.cochat.ai/papers/10.1183/09031936.03.00013303
- The paper
- Jones, P. W., Willits, L. R., Burge, P. S., & Calverley, P. M. A. (2003). Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. European Respiratory Journal. https://doi.org/10.1183/09031936.03.00013303
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.